|
|
Post by Clement on Oct 16, 2018 7:36:45 GMT -5
|
|
|
|
Post by uvula on Oct 16, 2018 7:45:33 GMT -5
Interesting. The trademark application was submitted over a year ago. I guess it was originally intended for a different PAH drug.
|
|
|
|
Post by tinkusr8215 on Oct 16, 2018 7:49:57 GMT -5
Not liking seeing it as medium term launch. Is medium term in 12 months or 12 to 24 months or 24+ months?
Does Mannkind / United have a time line as to when the trials SHOULD be done in the contract, so United doesnt drag the trials along?
|
|
|
|
Post by peppy on Oct 16, 2018 7:52:23 GMT -5
Not liking seeing it as medium term launch. Is medium term in 12 months or 12 to 24 months or 24+ months? Does Mannkind / United have a time line as to when the trials SHOULD be done in the contract, so United doesnt drag the trials along? I believe shareholders have been told, the FDA gave MNKD some feed back around trept. Fast track. |
|
|
|
Post by mnholdem on Oct 16, 2018 7:54:32 GMT -5
UTC has several clinical trials related to inhaled trepostinil, but you won't see any trademarks or brands mentioned in the government trial documents. Perhaps use of the word "Technosphere" in an upcoming Phase 3 trial will tip us off that recruitment for testing of the MannKind product has started.
I suspect that the inhaled trepostinil brand Spiresta has already been assigned to a different inhalation device. |
|
